Response Rate
Langer et al. al. ESMO 2016
•
Stage IIIb/IV
NSCLC
•
No systemic
therapy for
recurrent
disease
•
ECOG PS 0–1
(n=308 across all
cohorts)
Pemetrexed 500mg/m
2
i.v. q3w
+ carboplatin AUC 6 i.v.
q3w
+ pembrolizumab 200mg
i.v. q3w
Pemetrexed 500mg/m
2
i.v. q3w
+ carboplatin AUC 6 i.v.
q3w
1L immunotherapy plus CT:
pembrolizumab + CT vs CT (KEYNOTE-021)
